Chimeric antigen receptors: Driving immunology towards synthetic biology

Current Opinion in Immunology

Volumn 41, Issue , 2016, Pages 68-76

  Sadelain, Michel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE TRANSFER; CELL ENGINEERING; CELL EXPANSION; CELL THERAPY; COMPLEX FORMATION; GENETIC ENGINEERING; HUMAN; IMMUNOLOGY; MEMORY T LYMPHOCYTE; NONHUMAN; ONTOGENY; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SYNTHETIC BIOLOGY; T LYMPHOCYTE ACTIVATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; GENETICS; NEOPLASMS;

ANIMALS; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; RECEPTORS, ANTIGEN; SYNTHETIC BIOLOGY;

EID: 84976440434     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2016.06.004     Document Type: Review

References (105)

1. Mitchison N.A. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med 1955, 102:157-177.
2. Winn H.J. The immune response and the homograft reaction. Nat Cancer Inst 1959, Monograph No. 2:113-137.
3. Klein G., Sjogren H.O., Klein E., Hellstrom K.E. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 1960, 20:1561-1572.
4. Rosenberg S.A., Terry W.D. Passive immunotherapy of cancer in animals and man. Adv Cancer Res 1977, 25:323-388.
5. Miller J.F., Sadelain M. The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer Cell 2015, 27:439-449.
6. Butturini A., Bortin M.M., Gale R.P. Graft-versus-leukemia following bone marrow transplantation. Bone Marrow Transpl 1987, 2:233-242.
7. Champlin R. Immunobiology of bone marrow transplantation as treatment for hematologic malignancies. Transpl Proc 1991, 23:2123-2127.
8. Korngold R., Sprent J. Graft-versus-host disease in experimental allogeneic bone marrow transplantation. Proc Soc Exp Biol Med 1991, 197:12-18.
9. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
10. Greenberg P.D. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991, 49:281-355.
11. Old L.J. Tumor immunology: the first century. Curr Opin Immunol 1992, 4:603-607.
12. Melief C.J. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 1992, 58:143-175.
13. Sadelain M. From adoptive immunity to CAR therapy: an evolutionary perspective. Encylopedia of immunobiology 2016, 4:560-568. Academic Press, Oxford.
14. Grimm E.A., Mazumder A., Zhang H.Z., Rosenberg S.A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982, 155:1823-1841.
15. Grimm E.A., Robb R.J., Roth J.A., Neckers L.M., Lachman L.B., Wilson D.J., Rosenberg S.A. Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med 1983, 158:1356-1361.
16. Hromas R., Cornetta K., Srour E., Blanke C., Broun E.R. Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood 1994, 84:1689-1690.
17. Kolb H.J., Schattenberg A., Goldman J.M., Hertenstein B., Jacobsen N., Arcese W., Ljungman P., Ferrant A., Verdonck L., Niederwieser D., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86:2041-2050.
18. Rosenberg S.A., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986, 233:1318-1321.
19. Wu R., Forget M.A., Chacon J., Bernatchez C., Haymaker C., Chen J.Q., Hwu P., Radvanyi L.G. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 2012, 18:160-175.
20. Heslop H.E., Brenner M.K., Rooney C.M. Donor T cells to treat EBV-associated lymphoma. N Engl J Med 1994, 331:679-680.
21. Papadopoulos E.B., Ladanyi M., Emanuel D., Mackinnon S., Boulad F., Carabasi M.H., Castro-Malaspina H., Childs B.H., Gillio A.P., Small T.N., et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994, 330:1185-1191.
22. Melenhorst J.J., Castillo P., Hanley P.J., Keller M.D., Krance R.A., Margolin J., Leen A.M., Heslop H.E., Barrett A.J., Rooney C.M., et al. Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells. Mol Ther 2015, 23:179-183.
23. Sadelain M., Mulligan R.C. Efficient-retroviral-mediated gene transfer into murine primary lymphocytes [abstract no. 34]. Abstract: [8th] international congress of immunology, Budapest, Hungary, August 23-28, 1992. Edited by international congress of immunology, Magyar Immunológiai Társaság, International Union of Immunological Societies (IUIS) 1992, Springer-Verlag, Budapest/New York.
24. Mavilio F., Ferrari G., Rossini S., Nobili N., Bonini C., Casorati G., Traversari C., Bordignon C. Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood 1994, 83:1988-1997.
25. Bunnell B.A., Muul L.M., Donahue R.E., Blaese R.M., Morgan R.A. High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc Natl Acad Sci U S A 1995, 92:7739-7743.
26. Gallardo H.F., Tan C., Ory D., Sadelain M. Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood 1997, 90:952-957.
27. Riviere I., Brose K., Mulligan R.C. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci U S A 1995, 92:6733-6737.
28. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., Royal R.E., Topalian S.L., Kammula U.S., Restifo N.P., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
29. Hollyman D., Stefanski J., Przybylowski M., Bartido S., Borquez-Ojeda O., Taylor C., Yeh R., Capacio V., Olszewska M., Hosey J., et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother 2009, 32:169-180.
30. Savoldo B., Ramos C.A., Liu E., Mims M.P., Keating M.J., Carrum G., Kamble R.T., Bollard C.M., Gee A.P., Mei Z., et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Investig 2011, 121:1822-1826.
31. Wang X., Riviere I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncol 2016, 3:16015.
32. Poirot L., Philip B., Schiffer-Mannioui C., Le Clerre D., Chion-Sotinel I., Derniame S., Potrel P., Bas C., Lemaire L., Galetto R., et al. Multiplex genome-edited T-cell manufacturing platform for "Off-the-Shelf" adoptive T-cell immunotherapies. Cancer Res 2015, 75:3853-3864.
33. Schumann K., Lin S., Boyer E., Simeonov D.R., Subramaniam M., Gate R.E., Haliburton G.E., Ye C.J., Bluestone J.A., Doudna J.A., et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci U S A 2015, 112:10437-10442.
34. Menger L., Gouble A., Marzolini M.A., Pachnio A., Bergerhoff K., Henry J.Y., Smith J., Pule M., Moss P., Riddell S.R., et al. TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells. Blood 2015, 126:2781-2789.
35. Eyquem J., Mansilla-Soto J., Odak A., Sadelain M. One-step generation of universal CAR T cells. American society of gene & cell therapy 19th annual meeting 2016.
36. Ho W.Y., Blattman J.N., Dossett M.L., Yee C., Greenberg P.D. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 2003, 3:431-437.
37. Sadelain M., Riviere I., Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003, 3:35-45.
38. Eshhar Z., Waks T., Gross G., Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993, 90:720-724.
39. Brocker T., Peter A., Traunecker A., Karjalainen K. New simplified molecular design for functional T cell receptor. Eur J Immunol 1993, 23:1435-1439.
40. Sadelain M., Brentjens R., Rivière I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009, 21:215-223.
41. Gong M.C., Latouche J.B., Krause A., Heston W.D.W., Bander N.H., Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999, 1:123-127.
42. Brocker T. Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 2000, 96:1999-2001.
43. Sadelain M. CAR therapy: the CD19 paradigm. J Clin Invest 2015, 125:3392-3400.
44. Maher J., Brentjens R.J., Gunset G., Rivière I., Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat Biotechnol 2002, 20:70-75.
45. Imai C., Mihara K., Andreansky M., Nicholson I.C., Pui C.H., Geiger T.L., Campana D. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004, 18:676-684.
46. Jensen M.C., Riddell S.R. Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol 2015, 33:9-15.
47. Van Der Stegen S.J.C., Hamieh M., Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov 2015, 14:499-509.
48. Sadelain M., Brentjens R., Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013, 3:388-398.
49. Hinrichs C.S., Restifo N.P. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol 2013, 31:999-1008.
50. Morello A., Sadelain M., Adusumilli P.S. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov 2016, 6:133-146.
51. Kochenderfer J.N. Genetic engineering of T cells in leukemia and lymphoma. Clin Adv Hematol Oncol 2014, 12:190-192.
52. Ramos C.A., Savoldo B., Dotti G. CD19-CAR trials. Cancer J 2014, 20:112-118.
53. Wang J., Jensen M., Lin Y., Sui X., Chen E., Lindgren C.G., Till B., Raubitschek A., Forman S.J., Qian X., et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 2007, 18:712-725.
54. Carpenito C., Milone M.C., Hassan R., Simonet J.C., Lakhal M., Suhoski M.M., Varela-Rohena A., Haines K.M., Heitjan D.F., Albelda S.M., et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009, 106:3360-3365.
55. Zhong X.S., Matsushita M., Plotkin J., Riviere I., Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther 2010, 18:413-420.
56. Pule M.A., Straathof K.C., Dotti G., Heslop H.E., Rooney C.M., Brenner M.K. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005, 12:933-941.
57. Morgan R.A., Yang J.C., Kitano M., Dudley M.E., Laurencot C.M., Rosenberg S.A. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010, 18:843-851.
58. Till B.G., Jensen M.C., Wang J., Qian X., Gopal A.K., Maloney D.G., Lindgren C.G., Lin Y., Pagel J.M., Budde L.E., et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012, 119:3940-3950.
59. Zhao Z., Condomines M., van der Stegen S.J., Perna F., Kloss C.C., Gunset G., Plotkin J., Sadelain M. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 2015, 28:415-428.
60. Pegram H.J., Park J.H. Brentjens RJ: CD28z CARs and armored CARs. Cancer J 2014, 20:127-133.
61. Markley J.C., Sadelain M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 2010, 115:3508-3519.
62. Chinnasamy D., Yu Z., Kerkar S.P., Zhang L., Morgan R.A., Restifo N.P., Rosenberg S.A. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res 2012, 18:1672-1683.
63. Hoyos V., Savoldo B., Quintarelli C., Mahendravada A., Zhang M., Vera J., Heslop H.E., Rooney C.M., Brenner M.K., Dotti G. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010, 24:1160-1170.
64. Pegram H.J., Lee J.C., Hayman E.G., Imperato G.H., Tedder T.F., Sadelain M., Brentjens R.J. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012, 119:4133-4141.
65. Wilkie S., Burbridge S.E., Chiapero-Stanke L., Pereira A.C., Cleary S., van der Stegen S.J., Spicer J.F., Davies D.M., Maher J. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem 2010, 285:25538-25544.
66. Perna S.K., Pagliara D., Mahendravada A., Liu H., Brenner M.K., Savoldo B., Dotti G. Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res 2014, 20:131-139.
67. Krause A., Guo H.F., Latouche J.B., Tan C., Cheung N.K.V., Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med 1998, 188:619-626.
68. Prosser M.E., Brown C.E., Shami A.F., Forman S.J., Jensen M.C. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol Immunol 2012, 51:263-272.
69. Stephan M.T., Ponomarev V., Brentjens R.J., Chang A.H., Dobrenkov K.V., Heller G., Sadelain M. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 2007, 13:1440-1449.
70. Riese M.J., Wang L.C., Moon E.K., Joshi R.P., Ranganathan A., June C.H., Koretzky G.A., Albelda S.M. Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. Cancer Res 2013, 73:3566-3577.
71. Moon E.K., Ranganathan R., Eruslanov E., Kim S., Newick K., O'Brien S., Lo A., Liu X., Zhao Y., Albelda S.M. Blockade of programmed death 1 augments the ability of human T cells engineered to target NY-ESO-1 to control tumor growth after adoptive transfer. Clin Cancer Res 2016, 22:436-447.
72. Kochenderfer J.N., Dudley M.E., Kassim S.H., Somerville R.P.T., Carpenter R.O., Maryalice S.S., Yang J.C., Phan G.Q., Hughes M.S., Sherry R.M., et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015, 33:540-549.
73. Porter D.L., Hwang W.T., Frey N.V., Lacey S.F., Shaw P.A., Loren A.W., Bagg A., Marcucci K.T., Shen A., Gonzalez V., et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015, 7. 303ra139.
74. Sadelain M., Brentjens R., Riviere I., Park J. CD19 CAR therapy for acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book 2015, 35:e360-e363.
75. Di Stasi A., Tey S.K., Dotti G., Fujita Y., Kennedy-Nasser A., Martinez C., Straathof K., Liu E., Durett A.G., Grilley B., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011, 365:1673-1683.
76. Kim M.S., Ma J.S., Yun H., Cao Y., Kim J.Y., Chi V., Wang D., Woods A., Sherwood L., Caballero D., et al. Redirection of genetically engineered CAR-T cells using bifunctional small molecules. J Am Chem Soc 2015, 137:2832-2835.
77. Kudo K., Imai C., Lorenzini P., Kamiya T., Kono K., Davidoff A.M., Chng W.J., Campana D. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res 2014, 74:93-103.
78. Wu C.Y., Roybal K.T., Puchner E.M., Onuffer J., Lim W.A. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 2015, 350. aab4077.
79. Sun J., Sadelain M. The quest for spatio-temporal control of CAR T cells. Cell Res 2015, 25:1281-1282.
80. Spencer D.M., Wandless T.J., Schreiber S.L., Crabtree G.R. Controlling signal transduction with synthetic ligands. Science 1993, 262:1019-1024.
81. Fedorov V.D., Themeli M., Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med 2013, 5. 215ra172.
82. Kloss C.C., Condomines M., Cartellieri M., Bachmann M., Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013, 31:71-75.
83. Gordon W.R., Zimmerman B., He L., Miles L.J., Huang J., Tiyanont K., McArthur D.G., Aster J.C., Perrimon N., Loparo J.J., et al. Mechanical allostery: evidence for a force requirement in the proteolytic activation of notch. Dev Cell 2015, 33:729-736.
84. Morsut L., Roybal K.T., Xiong X., Gordley R.M., Coyle S.M., Thomson M., Lim W.A. Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell 2016, 164:780-791.
85. Roybal K.T., Rupp L.J., Morsut L., Walker W.J., McNally K.A., Park J.S., Lim W.A. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 2016, 164:770-779.
86. Themeli M., Sadelain M. Combinatorial antigen targeting: ideal T-cell sensing and anti-tumor response. Trends Mol Med 2016, 22.
87. Brentjens R.J., Latouche J.B., Santos E., Marti F., Gong M.C., Lyddane C., King P.D., Larson S., Weiss M., Rivière I., et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003, 9:279-286.
88. Adusumilli P.S., Cherkassky L., Villena-Vargas J., Colovos C., Servais E., Plotkin J., Jones D.R., Sadelain M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med 2014, 6. 261ra151.
89. Moeller M., Kershaw M.H., Cameron R., Westwood J.A., Trapani J.A., Smyth M.J., Darcy P.K. Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells. Cancer Res 2007, 67:11428-11437.
90. Oliveira G., Ruggiero E., Stanghellini M.T., Cieri N., D'Agostino M., Fronza R., Lulay C., Dionisio F., Mastaglio S., Greco R., et al. Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory. Sci Transl Med 2015, 7:317ra198.
91. Gattinoni L., Lugli E., Ji Y., Pos Z., Paulos C.M., Quigley M.F., Almeida J.R., Gostick E., Yu Z., Carpenito C., et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011, 17:1290-1297.
92. Klebanoff C.A., Gattinoni L., Restifo N.P. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?. J Immunother 2012, 35:651-660.
93. Graef P., Buchholz V.R., Stemberger C., Flossdorf M., Henkel L., Schiemann M., Drexler I., Hofer T., Riddell S.R., Busch D.H. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. Immunity 2014, 41:116-126.
94. Busch D.H., Frassle S.P., Sommermeyer D., Buchholz V.R., Riddell S.R. Role of memory T cell subsets for adoptive immunotherapy. Semin Immunol 2016, 28.
95. Riddell S.R., Sommermeyer D., Berger C., Liu L.S., Balakrishnan A., Salter A., Hudecek M., Maloney D.G., Turtle C.J. Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. Cancer J 2014, 20:141-144.
96. Sommermeyer D., Hudecek M., Kosasih P.L., Gogishvili T., Maloney D.G., Turtle C.J., Riddell S.R. Chimeric antigen receptor-modified T cells derived from defined CD8(+) and CD4(+) subsets confer superior antitumor reactivity in vivo. Leukemia 2016, 30:492-500.
97. Themeli M., Riviere I., Sadelain M. New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell 2015, 16:357-366.
98. Cruz C.R., Micklethwaite K.P., Savoldo B., Ramos C.A., Lam S., Ku S., Diouf O., Liu E., Barrett A.J., Ito S., et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 2013, 122:2965-2973.
99. Pule M.A., Savoldo B., Myers G.D., Rossig C., Russell H.V., Dotti G., Huls M.H., Liu E., Gee A.P., Mei Z., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008, 14:1264-1270.
100. Qasim W., Persis J., Samarasinghe S., Ghorashian S., Zhan H., Stafford S., Butler K., Ahsan G., Gilmour K., Pule M., et al. First clinical application of talen engineered universal CAR19 T cells in B-ALL [Abstract/Program: Oral and Poster Abstracts]. Presented at the 2015 American society of hematology conference 2015, Available from: https://ash.confex.com/ash/2015/webprogram/Paper81653.html.
101. Brudno J.N., Somerville R.P., Shi V., Rose J.J., Halverson D.C., Fowler D.H., Gea-Banacloche J.C., Pavletic S.Z., Hickstein D.D., Lu T.L., et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol 2016, 34.
102. Arnab G., Davila M.L., Young L.F., Kloss C., Gunset G., Smith O.M., West M.L., Singer N.V., Holland A.M., Jeng R.R., et al. CD19-targeted donor T cells exert potent graft versus lymphoma activity and attenuated Gvhd [Abstract/Program: Oral and Poster Abstracts]. Presented at the 54th American society of hematology annual meeting and exposition 2012, Available from: https://ash.confex.com/ash/2012/webprogram/Paper51817.html.
103. Nishimura T., Kaneko S., Kawana-Tachikawa A., Tajima Y., Goto H., Zhu D., Nakayama-Hosoya K., Iriguchi S., Uemura Y., Shimizu T., et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 2013, 12:114-126.
104. Vizcardo R., Masuda K., Yamada D., Ikawa T., Shimizu K., Fujii S., Koseki H., Kawamoto H. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells. Cell Stem Cell 2013, 12:31-36.
105. Themeli M., Kloss C.C., Ciriello G., Fedorov V.D., Perna F., Gonen M., Sadelain M. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol 2013, 31:928-933.